



## mRNA-Based Cancer Immunotherapy

Guest Editor:

**Dr. Werner Krause**

Bayer Pharma AG, Berlin,  
Germany

Deadline for manuscript  
submissions:

**closed (31 October 2023)**

### Message from the Guest Editor

Following the overwhelming success of mRNA-based vaccination in the COVID-19 pandemic, the focus of this technology has moved forward to alternative targets, including treatment of cancer. The major, initial hurdles for mRNA-based vaccines, such as instability of mRNA, inefficient delivery, weak immunogenicity, and large-scale production, have been resolved for the COVID-19 indication. For cancer, however, these issues need to be readdressed but should, hopefully, not constitute a major obstacle. In cancer indications, other challenges have to be overcome, such as selection of the tumor type, status and disease stage of patients, antigen(s) selection, packaging of the product (e.g., again using nanomaterials), route of administration, and immunological response and side effect rates. An additional important aspect that needs to be addressed is the feasibility of prophylactic administration of mRNA vaccination with the final objective of making therapeutic use no longer necessary. Authors in the field of mRNA-based immunotherapy are cordially invited to submit original research or review articles contributing to this important and fast-progressing area of biomedicine.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI